Fosun Pharma buys back 1.30 million H shares for HKD 22.24 million

Bulletin Express

Yesterday

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) disclosed that on 16 September 2026 it repurchased 1.30 million H shares on the Hong Kong Stock Exchange at prices ranging from HKD 16.91 to HKD 17.26 per share, with a volume-weighted average of HKD 17.11. The transaction cost totalled HKD 22.24 million.

Following the buy-back, the number of issued H shares (excluding treasury shares) fell by 0.24% to 533.51 million, while treasury shares increased to 18.43 million. The total issued share capital remained unchanged at 551.94 million shares.

The repurchase forms part of the mandate approved on 16 June 2026, which allows Fosun Pharma to buy back up to 54.10 million shares. Including the latest transaction, the company has repurchased 7.46 million shares under this mandate, representing 1.38% of the shares outstanding on the mandate date.

In accordance with Hong Kong listing rules, Fosun Pharma is subject to a 30-day moratorium—lasting until 16 October 2026—on issuing new shares or selling treasury shares after this repurchase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/news/1112089904"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112089904\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112089904?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-16 18:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112089904","market":"us","top_or_hot":-1,"title":"Fosun Pharma buys back 1.30 million H shares for HKD 22.24 million","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) disclosed that on 16 September 2026 it repurchased 1.30 million H shares on the Hong Kong Stock Exchange at prices ranging from HKD 16.91 to HKD 17.26 per share, with a volume-weighted average of HKD 17.11. The transaction cost totalled HKD 22.24 million.</p>\n<p>Following the buy-back, the number of issued H shares (excluding treasury shares) fell by 0.24% to 533.51 million, while treasury shares increased to 18.43 million. The total issued share capital remained unchanged at 551.94 million shares.</p>\n<p>The repurchase forms part of the mandate approved on 16 June 2026, which allows Fosun Pharma to buy back up to 54.10 million shares. Including the latest transaction, the company has repurchased 7.46 million shares under this mandate, representing 1.38% of the shares outstanding on the mandate date.</p>\n<p>In accordance with Hong Kong listing rules, Fosun Pharma is subject to a 30-day moratorium—lasting until 16 October 2026—on issuing new shares or selling treasury shares after this repurchase.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma buys back 1.30 million H shares for HKD 22.24 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma buys back 1.30 million H shares for HKD 22.24 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-16 18:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) disclosed that on 16 September 2026 it repurchased 1.30 million H shares on the Hong Kong Stock Exchange at prices ranging from HKD 16.91 to HKD 17.26 per share, with a volume-weighted average of HKD 17.11. The transaction cost totalled HKD 22.24 million.</p>\n<p>Following the buy-back, the number of issued H shares (excluding treasury shares) fell by 0.24% to 533.51 million, while treasury shares increased to 18.43 million. The total issued share capital remained unchanged at 551.94 million shares.</p>\n<p>The repurchase forms part of the mandate approved on 16 June 2026, which allows Fosun Pharma to buy back up to 54.10 million shares. Including the latest transaction, the company has repurchased 7.46 million shares under this mandate, representing 1.38% of the shares outstanding on the mandate date.</p>\n<p>In accordance with Hong Kong listing rules, Fosun Pharma is subject to a 30-day moratorium—lasting until 16 October 2026—on issuing new shares or selling treasury shares after this repurchase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1112089904","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112089904","pubTimestamp":1789553245,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) disclosed that on 16 September 2026 it repurchased 1.30 million H shares on the Hong Kong Stock Exchange at prices ranging from HKD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药以2224万港元回购130万股H股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) disclosed that on 16 September 2026 it repurchased 1.30 million H shares on the Hong Kong Stock Exchange at prices ranging from HKD 16.91 to HKD 17.26 per share, with a volume-weighted average of HKD 17.11. The transaction cost totalled HKD 22.24 million.\nFollowing the buy-back, the number of issued H shares (excluding treasury shares) fell by 0.24% to 533.51 million, while treasury shares increased to 18.43 million. The total issued share capital remained unchanged at 551.94 million shares.\nThe repurchase forms part of the mandate approved on 16 June 2026, which allows Fosun Pharma to buy back up to 54.10 million shares. Including the latest transaction, the company has repurchased 7.46 million shares under this mandate, representing 1.38% of the shares outstanding on the mandate date.\nIn accordance with Hong Kong listing rules, Fosun Pharma is subject to a 30-day moratorium—lasting until 16 October 2026—on issuing new shares or selling treasury shares after this repurchase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}